Scientists Discover a Molecular Switch That Helps Breast Cancer Hide From Immunotherapy

Immunotherapy has transformed the treatment of many cancers, but breast cancer has remained stubbornly resistant to one of its most powerful weapons: PD-1 blockade. Now, a team of researchers at Shinshu University in Japan has identified a surprising culprit that may help explain why. In a study published in the Journal of Translational Medicine, Yan Zhang, Megumu Tanaka, Takayuki Shindo and colleagues report that a little-studied molecule called receptor activity-modifying protein 3, or RAMP3, plays a central role in building an immunosuppressive fortress around breast tumors, physically and chemically excluding the immune cells that checkpoint inhibitors need in order to work. The findings, drawn from an unusually comprehensive combination of genetically engineered mouse models, single-cell RNA sequencing, spatial transcriptomics and human clinical data, point to RAMP3 as a potential new target for sensitizing breast cancers to immunotherapy.

RAMP3 was already known to cancer biologists as a player in stromal regulation, the management of the non-cancerous scaffolding tissue that surrounds and supports tumors. What remained murky was its role in remodeling the tumor microenvironment, the complex ecosystem of immune cells, fibroblasts, blood vessels and signaling molecules in which tumors live, and in shaping resistance to immune checkpoint blockade. The Shinshu team set out to answer two questions: whether RAMP3 actively shapes an immunosuppressive tumor microenvironment, and whether blocking it could improve responses to immunotherapy. Their strategy combined direct genetic manipulation in mice with high-resolution molecular atlasing of the resulting tumors, an approach that allows researchers to move beyond correlation and establish functional cause and effect.

The experimental core of the study was a set of syngeneic mouse models of breast cancer, in which tumors are transplanted into mice with intact immune systems, making them far more faithful stand-ins for human cancer than immunodeficient models. By genetically deleting RAMP3, the researchers could watch what happened to tumor progression, immune composition and therapeutic response. The results were striking. Loss of RAMP3 suppressed primary tumor growth, reduced the spread of cancer to the lungs, and significantly improved survival. These were not subtle shifts in cell culture dishes; they were whole-animal outcomes measured in vivo, which lends considerable weight to the biological relevance of the molecule.

To understand how removing a single protein could produce such dramatic effects, the team turned to single-cell RNA sequencing, a technique that profiles the gene activity of thousands of individual cells within a tumor, allowing researchers to identify every immune cell type present and the precise states those cells occupy. The analysis revealed a fundamental reprogramming of the tumor immune landscape. In tumors lacking RAMP3, the balance of tumor-associated macrophages, the abundant scavenger cells that tumors often corrupt into allies, shifted away from M2-like states, which are classically immunosuppressive and wound-healing in character, toward antigen-presenting macrophage states that display tumor fragments to the immune system and sound the alarm. At the same time, the researchers observed increased infiltration of CD8-positive T cells, the cytotoxic soldiers that directly kill cancer cells, along with a reduction in T cell exhaustion, the dysfunctional state that renders T cells impotent in immunosuppressive environments.

The mechanistic thread connecting these changes appears to run through a well-known immune signaling pathway. RAMP3 deficiency was associated with reduced IL-4/STAT6 signaling in macrophages. Interleukin-4 signaling through the STAT6 transcription factor is a canonical driver of M2-like macrophage polarization, so damping this pathway helps explain why macrophages in RAMP3-deficient tumors adopted a more immune-activating identity. Downstream of this shift, the researchers found decreased expression of immunosuppressive genes, most notably the chemokine CCL8, a signaling molecule that recruits and organizes cells within the tumor microenvironment. Chemokines act as molecular addresses, and CCL8 appears to be one of the addresses that helps assemble an immune-excluded architecture favorable to tumor growth.

Crucially, the team did not rely on genetics alone to make this point. When they pharmacologically inhibited the synthesis of CC chemokines, the drug treatment reproduced the effects of RAMP3 deletion, providing independent evidence that the CCL8-centered chemokine circuit is a functional driver of the immunosuppressive environment rather than a mere bystander. Spatial transcriptomic analysis, which maps gene expression onto physical locations within tissue, added a geographic dimension to the story: RAMP3 and CCL8 were found to be co-localized within the tumor microenvironment, suggesting that the two molecules operate together in the same tumor neighborhoods where immune exclusion takes place.

Perhaps the most clinically consequential finding concerns immunotherapy itself. PD-1 blockade works by releasing the molecular brakes on T cells, but it can only succeed if functional T cells are present in the tumor in the first place. In tumors where macrophages have walled off the immune system, checkpoint inhibitors have little to work with. The Shinshu researchers showed that RAMP3 deficiency enhanced the efficacy of PD-1 blockade in their mouse models, effectively converting a resistant tumor into one that responds to treatment. This positions RAMP3 not simply as another tumor suppressor or oncogene, but as a regulator of immunotherapy sensitivity, a category of target that has become one of the most sought-after prizes in translational oncology.

To test whether these mouse findings translate to human disease, the team analyzed data from The Cancer Genome Atlas breast cancer cohort, known as TCGA-BRCA, one of the largest publicly available collections of human tumor genomic and clinical data. They constructed a weighted risk score combining RAMP3 with CD163, a marker of M2-like macrophages, and CD8A, a marker of cytotoxic T cells, capturing the triad of molecular features their mouse work had implicated. Patients with a higher score had significantly poorer overall survival. Importantly, the association held up in complete-case multivariable Cox models adjusted for clinicopathological variables, meaning the RAMP3-associated signature carried prognostic information beyond standard clinical measures such as tumor stage and grade. This kind of cross-species validation, in which a mechanism discovered in mice leaves a detectable fingerprint in human survival data, is exactly the standard that promising therapeutic targets must meet.

The study also exemplifies a broader methodological trend reshaping cancer research. Rather than examining tumors through a single lens, the researchers integrated in vivo genetics, single-cell transcriptomics, spatial transcriptomics and human cohort analysis into one coherent narrative. Each technique compensates for the blind spots of the others: mouse models establish causality but may not fully recapitulate human disease; single-cell sequencing reveals cell states but loses spatial context; spatial transcriptomics restores geography but at lower resolution; and human datasets provide clinical relevance but only correlation. Weaving these threads together, the authors built a case for RAMP3 that is considerably stronger than any single approach could deliver.

Significant work remains before RAMP3 reaches the clinic. The study was conducted in mice and validated against retrospective human data; prospective clinical trials targeting the RAMP3 pathway in breast cancer patients have yet to be conducted, and the precise molecular partners through which RAMP3 acts, including its role as an accessory protein for receptor systems, will require further mechanistic dissection. Nevertheless, the convergence of evidence is compelling. A molecule that was, until now, a footnote in stromal biology has emerged as a plausible regulator of the immunosuppressive tumor microenvironment, a determinant of macrophage identity, a gatekeeper of T cell infiltration, and a modifier of PD-1 blockade response. If pharmacological strategies can be developed to inhibit RAMP3 function or its downstream CCL8-driven chemokine circuit in human tumors, the researchers suggest it could open a path to overcoming checkpoint resistance in a cancer type that has largely stood apart from the immunotherapy revolution. For the many breast cancer patients whose tumors exclude immune cells and resist PD-1 inhibitors, that path, however early, is one worth watching closely.

Subject of Research: The role of RAMP3 in macrophage-driven immune exclusion and resistance to PD-1 blockade in breast cancer

Article Title: RAMP3 is associated with macrophage-driven immune exclusion and promotes resistance to PD-1 blockade in breast cancer: integrated in vivo and single-cell transcriptomic analyses

Article References: Zhang, Y., Tanaka, M., Sakurai, T., Kamiyoshi, A., Ichikawa-Shindo, Y., Guo, Q., Hoshiyama, K., Li, P., Li, J., Duan, J., Hayashi, M., Kai, K., Zhao, Y., Dai, K., & Shindo, T. (2026). RAMP3 is associated with macrophage-driven immune exclusion and promotes resistance to PD-1 blockade in breast cancer: integrated in vivo and single-cell transcriptomic analyses. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09001-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09001-4

Keywords: RAMP3, breast cancer, tumor microenvironment, tumor-associated macrophages, PD-1 blockade, immune checkpoint resistance, CCL8, IL-4/STAT6 signaling, single-cell RNA sequencing, spatial transcriptomics, CD8-positive T cells, TCGA-BRCA